Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Myeloid 1

Conditions

Multiple Myeloma 5Leukemia, Hairy Cell 3Burkitt Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Carcinoma in Situ 2Breast Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Vomiting 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Sarcoma, Alveolar Soft Part 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Nausea and Vomiting 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Papillomavirus Infections 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm, Residual 1NSCLC 1Myelodysplastic Syndromes 1Mastocytosis, Systemic 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Cyclophosphamide 53Vincristine 33blinatumomab 30Prednisone 28Methotrexate 28Cytarabine 26Dexamethasone 24Specimen Handling 21Rituximab 21Doxorubicin 20merphos 19Mercaptopurine 19Etoposide 18prednylidene 17fludarabine 17deltacortene 17Calcium Dobesilate 17Biopsy 17dexamethasone acetate 16dexamethasone 21-phosphate 16auricularum 16N,N-dicyclohexyl-isoborneol-10-sulfonamide 16azathiopurine 15Inotuzumab Ozogamicin 15pegaspargase 14venetoclax 13Leucovorin 13CT-P10 13Asparaginase 13Spinal Puncture 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Burkitt Lymphoma × Diphenhydramine × 1 year × Clear all
NCT07570173 2026-05-26

MK-1045-005

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting
340 enrolled
Lymphoid

Burkitt Lymphoma

NCT03913559 2026-02-12

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

St. Jude Children's Research Hospital

Phase 2 Terminated
5 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04681105 2026-01-28

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

City of Hope Medical Center

Phase 1 Completed
13 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Mastocytosis, Systemic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡